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Accepted 11 October 2012AbstractObjective: Primary adenoid cystic carcinoma (ACC) of Bartholin’s gland is a rare gynecologic malignancy. We report two cases from primary
treatment to recurrence and the adjuvant treatment.
Case Report: Awoman aged 37 years presented with a mass on the right posterior labia minor and underwent right radical hemi-vulvectomy and
right-side inguino-femoral node dissection. Final pathology showed ACC arising from Bartholin’s gland with positive margins. She received
adjuvant external beam radiation to the pelvis, right vulva, and groin area. However, distal metastasis occurred 42 months after initial treatment
and she eventually died of multiple metastases. Another woman aged 48 years presented with a mass on the right posterior labia with intermittent
pain. She underwent right hemi-vulvectomy and right inguino-femoral lymph node dissection only because pathology showed ACC of Bar-
tholin’s gland with negative surgical margins. Lung metastasis occurred 59 months after initial treatment. She took tamoxifen only and achieved
stable disease status for 4 years.
Conclusion: To date, about 70 cases have been reported. We treated our second patient with antiestrogen therapy for 4 years and achieved good
quality of life and stable disease status. However, further study on hormone therapy for ACC of Bartholin’s gland is needed.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Primary carcinoma of Bartholin’s gland is a rare gyneco-
logic malignancy, comprising 0.001% of all female genital
malignancies and 2e7% of all vulvar carcinomas [1]. Among
all the reported cases, 10e15% had adenoid cystic carcinoma
(ACC), which is histologically similar to the adenocarcinoma* Corresponding author. Department of Obstetrics and Gynecology,
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http://dx.doi.org/10.1016/j.tjog.2012.10.005of the salivary glands [2]. To date, about 70 cases of ACC of
Bartholin’s gland have been reported. Herein, we report two
cases.Case reportsCase 1A 37-year-old female, gravida 5, para 2, presented with a
swelling on the right posterior labia minor associated with
intermittent tenderness. The patient recalled that the mass hadcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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after her second delivery. Physical examination found an indu-
rative, fixed, irregularmarginmass of about 4 cm 3 cmover the
right posterior labia minor, just at the site of Bartholin’s gland.
The mucosa was intact and no pus discharge or bleeding was
found. Pelvic bimanual examination revealed a normal cervix,
normal uterine size, and no palpable masses in the adnexa. The
patient’s laboratory data on admission, including complete blood
counts and kidney and liver functions,werewithin normal limits.
The chest X-ray was normal. Serum levels of tumor markers
CA125 and CEAwere also in the normal range before treatment.
A simple excision was arranged first, and an intraoperative
frozen section of the tumor revealed carcinoma. The patient
underwent a right radical hemi-vulvectomy and right-side
inguino-femoral node dissection with excision of a portion of
the vagina, ischiorectal fat, a portion of the levator ani and anal
sphincter because the firm, irregularly shaped mass extended to
the periostem of the inferior pubic ramus with close approxi-
mation to the anal sphincter.
The final pathology showed ACC arising from Bartholin’s
gland. The tumor had invaded deep into the stroma of the
vagina with extensive perineural invasion and skeletal muscle
infiltration. Immunohistochemical (IHC) stains for the estro-
gen receptor and progesterone receptor were negative. The
margins of the resection were positive. Two of 12 right
inguinal lymph nodes were metastatic. An abdomino-pelvic
computerized tomography scan 2 weeks after surgery
showed no residual mass or abnormal inguinal lymph node
enlargement. The patient received postoperative adjuvant
external beam radiation (a total of 7000 cGy over 35 fractions)
to the pelvis, right vulva, and groin area.
After radiation, she maintained regular outpatient surveil-
lance every 3 months. Unfortunately, distant metastasis was
found 42 months after initiation of the adjuvant radiation
therapy. The patient complained of right thigh and ankle pain.
A technetium-99m-methylene diphosphonate (Tc99m-MDP)
whole body bone scan revealed multiple bone metastases. An
irregular mass lesion over the left lower lobe of the lung was
noted on lung computerized tomography scan. Subsequent
bronchoscopic biopsy proved metastatic ACC. A positron
emission tomography (PET) scan detected fluorodeoxyglucose
(FDG)-avid lesions in the right mastoid, left occipital regions,
right clavicle, upper cervical spine, 9th thoracic vertebra, 2nd
and 4th lumbar vertebrae , right iliac bone, right proximal
femoral shaft, bilateral acetabula, and left lower lobe of the
lung. The patient’s serum CA125 elevated to 139 units/mL and
correlated with disease progression. Chemotherapy was
commenced. She received one cycle of combination chemo-
therapy consisting of taxol (135 mg/m2) and cisplatin (60 mg/
m2), but anaphylactic shock occurred in the second chemo-
therapy course. Taxol was replaced by taxotere. However,
erythematous, well-demarcated, raised skin lesions appeared
30 minutes after the start of chemotherapy. Owing to the pa-
tient’s type I allergy reaction, chemotherapy was discontinued.
One month later, radiotherapy (a total of 2450 cGy over 7
fractions) to the spine lesion, right iliac fossa, and right femoral
shaft was arranged for relief of bone pain. Then, palliativechemotherapy with two courses of carboplatin and two courses
of carboplatin and lipodox was arranged. Unfortunately, further
disease progression, massive ascites, right chest wall and brain
metastases followed, and the patient died of multiple metas-
tases. The overall disease survival was 54 months.Case 2A 48-year-old married woman, gravida 4, para 3, noted
right labium minor intermittent pain for the past 3 months after
riding a bicycle. The patient first sought medical attention at a
local hospital, and marsupialization of the right Bartholin’s
gland was arranged. A biopsy revealed ACC. The tumor size
was about 2 cm  2 cm  1 cm. The patient was then referred
to our hospital. Pelvic examination showed an ill-defined firm
nodule over the right labia minor measuring 1.5 cm  1.5 cm.
Physical examination did not reveal other abnormalities. Chest
X-ray, hematological, renal, and liver functions were all
normal. The patient’s serum level of CA125 was also in the
normal range. The patient underwent a right hemi-vulvectomy
with partial resection of the lower third of the vagina, right-
side levator ani muscle and right inguinalefemoral lymph
node dissection. An intraoperative frozen section was sent to
the laboratory to confirm the free resection margin. Final pa-
thology confirmed the diagnosis of ACC of Bartholin’s gland
with free surgical margin. There was no inguinalefemoral
lymph node metastasis. No adjuvant radiation therapy was
performed. One year later, owing to uterine and vaginal pro-
lapse on the right side, total vaginal hysterectomy, bilateral
salpingo-oophorectomy, sacrospinous ligament suspension,
and anterior colporrhaphy were arranged. During this surgery,
no tumor recurrence was found. Unfortunately, lung metastasis
with bilateral multiple cotton ball lesions was found 59
months after the first operation. The patient refused further
chemotherapy and took tamoxifen for 4 years with stable
disease status. Dyspnea progressed, however, and she died
from respiratory failure due to lung metastasis 6 months later.
Overall disease survival was 120 months.
Discussion
Primary carcinoma of Bartholin’s gland, first documented
by Klob in 1864, is a rare malignant tumor comprising 0.001%
of all female genital malignancies and 2-7% of all vulvar
carcinomas [3,4]. Clinical diagnosis was established by Honan
in 1897 [4,5]. It included adenocarcinoma of various types
(papillary, mucinous, and colloid) and squamous cell carci-
noma; 10-15% cases had ACC, which is histologically similar
to the adenocarcinoma of the salivary glands.
ACC, first recognized in 1859 by Billroth, is a specific
variant of adenocarcinoma of the salivary and mucous glands
[4,6]. It is found in various locations such as the salivary
glands, breasts, skin, and lungs. In the female genital tract,
ACC is more commonly found in the cervix. The ACC of
Bartholin’s gland is a rare variant. Typical symptoms are
similar to those of a Bartholin’s gland abscess, including a
painless lump in the posterior half of the vulva with or without
Fig. 2. H&E stain (400). Tumor cells are of low grade with only mild
cytologic atypia and small nucleoli. This characteristic is compatible with the
notorious feature of adenoid cystic carcinoma. Low-grade cytologic abnor-
malities with advanced infiltrative growth pattern are shown.
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rarely, vulvar pain [7]. Half of the cases of carcinoma of
Bartholin’s gland (12 of 24) were initially clinically mis-
diagnosed as cysts or abscesses [8].
The clinical diagnosis of a Bartholin’s gland tumor includes
the tumor located in the Bartholin’s gland region, overlying
skin intact, tumor located deep in the labia major, normal
glandular elements present on histology, areas of apparent
transition from normal to neoplastic elements, histological
tumor type consistent with the Bartholin’s gland origin and no
evidence of a previous, concurrent, or subsequent primary
tumor of similar histologic type elsewhere [9]. When the
tumor progresses, the overlying skin may become ulcerated
[4]. Owing to the limited number of cases, it is difficult to
identify the risk factors of ACC of Bartholin’s gland, but
pregnancy may be a factor.
Microscopically, ACC of Bartholin’s gland exhibits the
classic “cribriform” adenoid cystic pattern, characterized by
anastomosing cords of cells, often surrounding acellular
spaces. The acellular area contains variable amounts of mucin
and hyalinized material. In addition, solid cellular and tubulo-
glandular patterns of similar cell types are present. The tumor
cells, small and basaloid, have regular nuclei and little cyto-
plasm. In addition, there may be residual normal Bartholin’s
gland elements with areas suggestive of transition into
neoplastic tissue [9]. The infiltration of perineural spaces is
another main microscopic feature of this type of tumor (Figs. 1
and 2). Thus, many patients experience itching and burning
sensations before a mass becomes palpable at physical ex-
amination [2,10].
The ACC of Bartholin’s gland is a slow-growing tumor
with late clinical presentation of recurrence and distant
metastasis. According to Copeland et al., the 5-year
progression-free interval is 47% and the 5-year survival rate
is 71%. The progression-free intervals and survival rates are
38% and 50% at 10 years, and 13% and 51% at 15 years,
respectively [9]. From these results, 5-, 10-, and 15-year
progression-free survival interval rates rather than 5-year
survival rates for ACC of Bartholin’s gland are recommended.
There is currently no consensus regarding the optimal
surgical treatment for ACC of Bartholin’s gland. Both simpleFig. 1. H&E stain (200). Perineural invasion of atypical cribriform glands.excision and radical vulvectomy with or without lymph node
dissection have been performed. According to the experience
of Lelle et al, if an adequate surgical margin can be achieved, a
more conservative surgical procedure with adjuvant radiation
may be reasonable [11]. According to the review by Yang
et al, 68.9% of patients who had a simple excision had re-
currences compared with 42.9% of patients who had a radical
vulvectomy. Although the information on the status of margins
at the initial surgery was incomplete, the positivity of resection
margin was 48% in the simple excision group and 30% in the
radical vulvectomy group [12]. Following the review of Yang
et al, we included the new cases reported in the last 5 years
and conducted a new review of surgical intervention (Table 1)
[13,14]. Radical vulvectomy can reduce local recurrence, but
it has no impact on distant metastasis.
Adjuvant radiation does lower the incidence of local
recurrence in patients with positive resection margins.
Rosenberg et al and Copeland et al reported the benefits of
postoperative external beam radiation for patients with
positive margin.[9,15]. In the literature, 16 patients received
adjuvant radiotherapy, the 10 patients with positive resection
margins did not have local recurrence, but six of them
developed distant metastasis (Table 1).
With regard to primary radiation or concurrent chemo-
radiation, Lopez-Varela et al conducted a study at Massa-
chusetts General Hospital (MGH) about primary treatment of
Bartholin’s gland carcinoma with radiation or chemoradiation.
The median follow-up was 87.2 months (45-142). Three- and
5-year survival rates were 71.5% and 66%, respectively, and
were comparable with outcomes after surgery and post-
operative radiation therapy. The authors conclude that primary
radiation or chemoradiation therapy offers an effective alter-
native to surgery with preservation of genital function and low
morbidity [16].
The clinical course of ACC of Bartholin’s gland appears to
be different from that of adenocarcinoma and squamous cell
carcinoma of Bartholin’s gland. Metastatic disease to the
Table 1
Adenoid cystic carcinoma of Bartholin’s gland: primary treatment, resection margins, and recurrence.
Treatment Positive resection margin Recurrence Local recurrence Distant metastasis
Primary treatment d d d d
Simple excision (n ¼ 35) 13 (48.1%), NM, 8 21(67.7%), NM ,4 17 (54.8%) 10 (32.3%) (4, lung; 3, bone; 1, mediastinum)
Radical vulvectomy (n ¼ 32) 7 (31.8%), NM, 10 14 (46.7%), NM, 2 4 (13.3%) 11 (36.7%) (8, lung; 5, bone; 1, skull; 1,
brain; 1, liver)
Adjuvant treatment d d d d
Radiotherapy (n ¼ 16) 10 (66.7%), NM, 1 6 (40.0%), NM, 1 0 (0%) 6 (40%) (6, lung; 3, bone; 1, liver; 1, brain)
NM ¼ not mentioned.
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togenous route. The most common metastatic site is the lung
[4,12,17,18]. In the review by Bernstein et al. [3], five of 20
patients died from lung metastasis 4-23 years after initial
treatment. Yang et al used six cycles of cyclophosphamide,
Adriamycin, and cisplatin for one patient with lung metastasis,
achieving only stable disease status [12]. According to a re-
view of chemotherapy for ACC of the head and neck, the
response rates to chemotherapy are low and the response
duration is generally short. No standard chemotherapy
regimen was recommended [19].
We treated our patient (Case 2) with tamoxifen for 4 years
and achieved stable disease status. According to Copeland
et al, seven of 14 patients aged below 42 years had their
adenoid cystic vulvar tumor diagnosed in association with
pregnancy [9]. Dramatic hormonal change may induce cancer,
and hormone therapy may play a role in the treatment of ACC
of Bartholin’s gland. We used antiestrogen therapy owing to
the strong relation between pregnancy and this tumor, as
mentioned in Copeland’s review series [9]. Clearly, further
studies on hormone therapy are required.
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